Calumet, Inc.
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Calumet, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 17.70 $ to 59.10 $ · Last price: 59.10 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Specialty Chemicals
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Calumet, Inc. CLMT | 5.2 | – | 92.3 | 6.9 | -27.8 | -1.3 | 214.7 |
| Linde plc LIN | 212.0 | 30.6 | 17.5 | 48.4 | 28.5 | 3.0 | -3.2 |
| Sherwin-Williams Co SHW | 77.7 | 31.5 | 19.5 | 49.0 | 14.2 | 2.1 | -7.5 |
| Ecolab Inc ECL | 76.7 | 37.6 | 21.6 | 44.2 | 16.9 | 2.2 | 3.5 |
| Air Products and Chemicals Inc APD | 64.1 | 30.2 | 48.8 | 32.1 | 23.6 | -0.5 | 1.1 |
| PPG Industries Inc PPG | 23.5 | 15.3 | 10.4 | 41.2 | 13.7 | 0.2 | -0.6 |
| International Flavors & Fragrances Inc. IFF | 21.7 | 26.8 | 59.0 | 36.6 | 10.1 | -5.2 | 37.3 |
| LyondellBasell Industries NV LYB | 21.1 | – | 16.7 | 12.9 | 3.5 | -25.2 | 27.6 |
| Sociedad Quimica y Minera de Chile SA SQM | 20.5 | 25.3 | 8.6 | 42.2 | 41.1 | 0.9 | 60.5 |
| Median of companies shown | 23.5 | 30.2 | 19.5 | 41.2 | 14.2 | 0.2 | 3.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3,599 | -40 | -329 | -4.27 | 4 | 219 | 2,725 |
| 2017 | 3,764 | 158 | -104 | -1.34 | -27 | 120 | 2,689 |
| 2018 | 3,498 | 123 | -55 | -0.71 | 75 | -9 | 2,088 |
| 2019 | 3,453 | 76 | -44 | -0.56 | 192 | 10 | 1,858 |
| 2020 | 2,268 | -72 | -149 | -1.90 | 63 | -138 | 1,808 |
| 2021 | 3,148 | -86 | -255 | -3.23 | -44 | -389 | 2,128 |
| 2022 | 4,686 | 132 | -170 | -2.14 | 101 | -534 | 2,741 |
| 2023 | 4,181 | 267 | 48 | 0.60 | -15 | -492 | 2,751 |
| 2024 | 4,189 | 8 | -222 | -2.67 | -46 | -713 | 2,758 |
| 2025 | 4,137 | 54 | -34 | -0.39 | 109 | -733 | 2,689 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.47 | – | 950 | -2.80 | -4.30 | -3 | -28 |
| 2025: Q1 | -1.87 | – | 994 | -12.30 | -16.30 | -111 | -128 |
| 2025: Q2 | -1.70 | – | 1,027 | -9.40 | -14.40 | 3 | -11 |
| 2025: Q3 | 3.61 | – | 1,078 | -2.00 | 29.10 | 100 | 92 |
| 2025: Q4 | -0.43 | – | 1,039 | 9.40 | -3.60 | 117 | 104 |
| 2026: Q1 | -3.64 | – | 1,030 | 3.60 | -30.80 | -86 | -99 |
| 2026: Q2 | -1.09 | 35.90 | 1,445 | 40.80 | -6.60 | 92 | 54 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- Richard Moglen: Top Performers 3/6 Month
- Stan Weinstein: Stage 2
- Strength on Stress Days
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.68 | -2.68 – -2.68 | 4,932 | -466.5% | 1 |
| 12/31/2027 | 0.63 | 0.63 – 0.63 | 4,690 | 123.5% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 15.2% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $150.4M |
|---|---|
| Market cap | $5.22B |
| Free cash flow in year ten | $619.5M |
| Terminal value as a share of market value | 62.5% |
For comparison: over the past five years free cash flow grew by 24.7% per year.
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -4.1%
- More than 10% revenue growth is expected for the coming year 5.0%
- Share count grows by less than 3% a year 3.0%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.1%
- Gross margin at 40% or higher and without meaningful erosion 5.9%
- Goodwill from acquisitions does not grow faster than revenue 5.2%
- Net debt below twice EBITDA 9.8 x EBITDA
- Operating cash flow covers the profits of the last three years 255 m
- Return on capital at 15% or higher, or up versus two years ago 2.9%
- Insiders hold at least 10% or are net buyers 20.3%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 1.6%
- Exp. sales growth 3Y > 5% 6.5%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 6.5%
- Net debt < 4x EBIT 43.1x
- EBIT positive, 10Y straight 7
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% –
- ROCE > 15% 2.9%
- Expected return > 10% 7.6%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Boss John G. | Director | Other | 2,827 | 0.00 | – |
| Jul 9, 2026 | Boss John G. | Director | Other | 7,067 | 0.00 | – |
| Jul 9, 2026 | Mawer Stephen P | Director | Other | 5,512 | 0.00 | – |
| Jul 9, 2026 | Mawer Stephen P | Director | Other | 13,780 | 0.00 | – |
| Jul 9, 2026 | Raymond Paul C | Director | Other | 2,827 | 0.00 | – |
| Jul 9, 2026 | Raymond Paul C | Director | Other | 7,067 | 0.00 | – |
| Jul 9, 2026 | Sajkowski Daniel J | Director | Other | 2,827 | 0.00 | – |
| Jul 9, 2026 | Sajkowski Daniel J | Director | Other | 7,067 | 0.00 | – |
| Jul 9, 2026 | Schumacher Amy M | Director | Other | 7,067 | 0.00 | – |
| Jul 9, 2026 | Quintana Julio M | Director | Other | 7,067 | 0.00 | – |
The company
About the Company
Calumet, Inc. fertigt, formuliert und vermarktet ein Sortiment spezialisierter Markenprodukte und erneuerbarer Kraftstoffe in Nordamerika und international.
- Employees
- 1,540
- Headquarters
- Indianapolis, IN
- Address
- 1060 N Capitol Ave., 46204-1044 Indianapolis, United States
- Phone
- 317 328 5660
- Website
- calumet.com
- IPO Date
- 01/26/2006
- ISIN
- US1314281049
- Stock Split
- 1:1 on 07/11/2024
Management
| Name | Title | Birth Year |
|---|---|---|
| Louis Todd Borgmann | President, CEO & Director | 1983 |
| David A. Lunin | Executive VP & CFO | 1981 |
| Gregory J. Morical | Senior VP, General Counsel & Secretary | 1969 |
| Bruce A. Fleming Ph.D. | Executive Vice President of Montana Renewables & Corporate Development | 1957 |
| Scott Obermeier | President of Specialties | 1973 |
| John Robert Krutz | Chief Accounting Officer | 1976 |
| John Kompa | Director of Investor Relations | – |
| Chris Hodges | Alpha IR | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 09/14/2026 Calumet, Inc. /DE (CLMT): Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Financial Statements and Exhibits SEC ↗
- 09/01/2026 Calumet, Inc. /DE (CLMT): Entry into a Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/07/2026 Calumet, Inc. /DE (CLMT): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.